{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000182","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-10-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.019381+00:00","generated_at":"2026-06-09T11:38:43.979411+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Centessa presents ORX750 preclinical data; shows potential best-in-class profile for narcolepsy","bullets":["ORX750 potently activates OX2R with EC50 of 0.11 nM and 9,800-fold selectivity over OX1R.","Oral doses as low as 0.1 mg/kg achieved 100% wake time for ≥3 hours and suppressed cataplexy for ≥6 hours in mouse models.","Effects on wake and cataplexy latency maintained for >14 days of dosing.","Clinical proof-of-concept data planned for 2024; IND-enabling studies ongoing.","Preclinical PK profile suggests high, early, and sustained brain exposure in multiple species."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000182","json":"https://secwatch.observer/filing/0001847903-23-000182.json","markdown":"https://secwatch.observer/filing/0001847903-23-000182.md","text":"https://secwatch.observer/filing/0001847903-23-000182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/0001847903-23-000182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000182/cnta-20231025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T11:38:43.979411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}